Colorado BioScience Association Announces Nine New Board Members

Business Wire, May 2, 2008

DENVER -- Nine new board members have been elected to the Colorado BioScience Association (CBSA) 40-member Board of Directors. The announcement is made by Chris Shapard, CBSA Deputy Director, who says the election occurred at the Association's recent 2008 All-Member Meeting.

Newly elected CBSA board members include: Jim Chrisman, Senior Vice President, Forest City -- http://www.fitzscience.com; John Dunning, President and CEO, Clarimedix; Leslie Leinwand, Director, Colorado Initiative in Molecular Biotechnology and Professor, MCD Biology Department, University of Colorado -- http://www.colorado.edu; Terry Opgenorth, Chief Operating Officer, MicroRx and NeoTREX, Colorado State University Research Foundation -- http://www.csurf.org; John Poate, Vice President for Research and Technology Transfer, Colorado School of Mines - http://www.mines.edu; Rae Reynolds, President, Kaleidoscope Group; Jim Skrine, Executive Director of Quality, Amgen -- http://www.amgen.com; Rulon Stacey, President and CEO, Poudre Valley Health System -- http://www.pvhs.org; and Dan Stinchcomb, Chief Executive Officer and Co-Founder, Inviragen -- http://www.inviragen.com.

Bios follow of the new CBSA board members:

* Jim Chrisman is the Senior Vice President for Forest City, the development company working in partnership with the Fitzsimons Redevelopment Authority to create a nationally and internationally renown life science park. Chrisman is the principal in charge of the Fitzsimons project on behalf of Forest City. In addition, he is responsible for office, retail, industrial and multi-family development at the former Stapleton International Airport which Forest City is transforming into a new community of 12,000 homes, 35,000 jobs and more than 1,100 acres of parks and open space. Prior to joining Forest City Stapleton, Inc., Chrisman worked as a Vice President for the Stapleton Development Corporation, where he managed the conveyance of the property from the City and County of Denver to the private sector and the Stapleton Redevelopment Foundation, where he managed the preparation of the award winning Stapleton Development Plan. Prior to that, he worked for Disney Development Company, Watt Industries, and Cadillac Fairview Corporation in southern California. He is currently on the Board of Directors of the local chapter of the National Association of Office and Industrial Properties. He holds a Bachelor of Science in Applied Mathematics and Administration and Management Science from Carnegie-Mellon University and a M.B.A. from the University of California, Berkeley.

* John Dunning is President and CEO of CLARIMEDIX INC, a therapeutic medical device company based in Boulder, CO. Dunning brings a diverse background with significant start-up experience and an understanding of the financing and management processes associated with equity-backed companies. Prior to his time with CLARIMEDIX, he was an investor at Wasatch Venture Fund, where he focused on a mixture of life science and technology investing while successfully raising a $12 million side car fund for Wasatch. Prior to joining Wasatch, Dunning contributed at several start-ups in the San Francisco Bay Area where he had roles in operations and business development. He holds a B.A from the University of Oregon and an M.B.A. from Thunderbird, the American Graduate School of International Management.

* Dr. Leslie Leinwand is a Molecular, Cellular, and Developmental Biology (MCDB) Professor and Director of the Colorado Initiative in Molecular Biotechnology. She has been at the University of Colorado since 1995. She was recruited here to be Chair of MCDB. She received her Bachelor's degree from Cornell University, her PhD from Yale University and did post-doctoral training at Rockefeller University. She joined the faculty at Albert Einstein College of Medicine in New York in 1981 and remained there until moving to Colorado. While at Albert Einstein she became a Full Professor and was Director of the Cardiovascular Research Center. Once moved to Colorado, along with Michael Bristow, she founded the intercampus University of Colorado Cardiovascular Institute which promotes research and training in cardiovascular disease. They, along with Eric Olson at the University of Texas, Southwestern Medical Center, founded Myogen, Inc. which was recently sold to Gilead Pharmaceuticals. Her work as a cardiac biologist is of importance to both basic scientists and clinicians. The interests of Dr. Leinwand's laboratory are the genetics and molecular physiology of inherited diseases of the heart. The study of these diseases has required multidisciplinary approaches, involving molecular biology, mouse genetics, mouse cardiac physiology, and the analysis of human tissues. To accomplish this, Dr. Leinwand has developed a highly collaborative group in Boulder, bringing together specialized basic scientists and clinical cardiologists. Her laboratory's efforts are well-funded by multiple grants from the National Institutes of Health and her teaching is recognized by funding from the Howard Hughes Medical Institute's Professor Program. She is also the Principle Investigator of the HHMI program called the Biological Sciences Initiative which supports undergraduate research, K-12 outreach and educational programs for high school teachers.